⌘K

Home/Filings/4/0001127602-25-009263

4//SEC Filing

Berger Dietmar 4

Accession 0001127602-25-009263

CIK 0000882095other

View on SEC.gov Company Profile

Filed

Mar 11, 8:00 PM ET

Accepted

Mar 12, 6:04 PM ET

Size

7.7 KB

Accession

0001127602-25-009263

Insider Transaction Report

Form 4

Period: 2025-03-10

GILEAD SCIENCES, INC.GILD

Chief Medical Officer

Transactions

Award
Restricted Stock Unit
2025-03-10+8,530→ 57,505 total
→ Common Stock (8,530 underlying)
Award
Non-qualified Stock Option (Right to Buy)
2025-03-10+37,710→ 37,710 total
Exercise: $117.21Exp: 2035-03-10→ Common Stock (37,710 underlying)

Footnotes (3)

[F1]Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
[F2]The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
[F3]The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT

Issuer

GILEAD SCIENCES, INC.

CIK 0000882095

Entity typeother

Related Parties

1

filerCIK 0001739515

Filing Metadata

Form type: 4
Filed: Mar 11, 8:00 PM ET
Accepted: Mar 12, 6:04 PM ET
Size: 7.7 KB

View on SEC.gov